• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on NewAmsterdam Pharma with a new price target

    12/30/24 7:25:48 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NAMS alert in real time by email
    H.C. Wainwright initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $48.00
    Get the next $NAMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAMS

    DatePrice TargetRatingAnalyst
    6/17/2025$42.00Buy
    Citigroup
    6/10/2025$44.00Buy
    Stifel
    6/4/2025$42.00Overweight
    Cantor Fitzgerald
    12/30/2024$48.00Buy
    H.C. Wainwright
    5/15/2024Buy
    TD Cowen
    3/14/2024$35.00Sector Outperform
    Scotiabank
    1/18/2024$30.00Buy
    Guggenheim
    1/16/2024$37.00Overweight
    Piper Sandler
    More analyst ratings

    $NAMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Topper James N bought $167,381 worth of Ordinary Shares (8,584 units at $19.50) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      6/18/25 4:42:40 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $25,521 worth of Ordinary Shares (1,135 units at $22.49) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/28/25 5:36:48 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Topper James N bought $84,203 worth of Ordinary Shares (4,005 units at $21.02) (SEC Form 4)

      4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)

      3/6/25 5:32:07 PM ET
      $NAMS
      Biotechnology: Pharmaceutical Preparations
      Health Care